Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Deucrictibant - Pharvaris

Next Previous
Drug Profile

Deucrictibant - Pharvaris

Alternative Names: PHA-022121; PHA-121; PHVS 416; PHVS 719; PHVS416 - soft capsule formulation; PHVS719 - XR tablet

Latest Information Update: 08 Aug 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Pharvaris
  • Class Acetamides; Benzene derivatives; Ethers; Halogenated hydrocarbons; Organic deuterium compounds; Quinolines; Skin disorder therapies; Small molecules; Triazoles; Vascular disorder therapies
  • Mechanism of Action Bradykinin B2 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Hereditary angioedema; Angioedema
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Acquired angioedema; Hereditary angioedema

Most Recent Events

  • 08 Aug 2025 Phase-III clinical trials in Acquired angioedema (unspecified route), prior to August 2025 (Pharvaris pipeline, August 2025)
  • 10 Jul 2025 Pharvaris announces intention to submit NDA to US FDA for hereditary angioedema in first half of 2026
  • 30 Jun 2025 Pharvaris completes the phase-II CHAPTER-1 trial in Hereditary angioedema (Prevention) in the US, Canada, Bulgaria, Germany, Italy, Poland, Austria, Ireland and United Kingdom (PO) (NCT05047185) (EudraCT2021-000227-13)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top